CoImmune

CoImmune is a United States-based clinical-stage biotechnology company located in Durham, North Carolina. The company is focused on the research, development and commercialization of cell-based immunotherapies, a field that seeks to harness or engineer components of the patient's immune system to recognize and attack cancer and other serious diseases. Its pipeline and technology platforms are built around cellular immunotherapy approaches, including dendritic cell-based and other immune-cell engineering strategies. As a clinical-stage enterprise, CoImmune's activities center on translational research, preclinical development and early-phase human clinical trials rather than on marketed pharmaceutical products. The company operates within the broader immuno-oncology and advanced therapy sector, a highly competitive space populated by academic spin-outs, dedicated cell-therapy companies and the immunotherapy divisions of large pharmaceutical corporations. Companies in this segment typically depend on a combination of private investment, partnership deals and public research funding to advance candidates through the regulatory process. CoImmune's corporate identity is closely tied to its Durham, North Carolina location, part of the Research Triangle region that hosts a dense cluster of biotechnology firms, contract research organizations and university research programs. The company's website, coimmune.com, serves as its primary public communications channel for pipeline information, scientific publications and corporate updates. Because CoImmune is a privately held, development-stage company, detailed financial disclosures are limited, and its visibility rests primarily on its scientific programs and clinical progress rather than on consumer-facing products or brand marketing.

CoImmune is a clinical-stage biotechnology company based in Durham, North Carolina, in the United States. The company operates in the field of cellular immunotherapy, developing treatments intended to mobilize or engineer the immune system against cancer and other serious diseases. Its location places it within the Research Triangle, one of the largest and most active life-science clusters in the United States, home to major research universities, contract research organizations and a large concentration of biotechnology and pharmaceutical companies. As a development-stage enterprise, CoImmune's history is defined less by commercial product launches than by the progression of its scientific programs through preclinical research and clinical trials. Companies of this type typically advance candidates from laboratory discovery through investigational new drug applications and early-phase human studies, a capital-intensive and lengthy process that shapes their corporate development, financing and partnership strategies. CoImmune's public profile is therefore tied to its pipeline milestones, scientific presentations and collaborations rather than to marketed therapies. The company maintains a corporate website at coimmune.com, which serves as its principal channel for describing its technology platforms, pipeline and corporate information. Because CoImmune is privately held and clinical-stage, it does not publish the extensive financial reports required of publicly listed corporations, and its ownership structure and detailed financial history are not part of the public record in the same way as those of larger, listed biotechnology firms. Its identity in public databases, including Wikidata, is recorded simply as a company located in Durham, United States, reflecting its status as a privately held, development-focused enterprise rather than a large commercial brand.

Clinical-stage biotechnology company focused on cellular immunotherapy for cancer and serious diseases.

• Cellular immunotherapy programs

  Clinical-stage cell-based therapeutic candidates for cancer and other serious diseases.

• 2021-07-06

  CoImmune appoints two directors to its board[3]CoImmune 任命两名董事加入董事会finanznachrichten.de

  Reported: 2021-07-06

  CoImmune announced the appointments of Michael Fekete and Greg Tibbitts to the company's board of directors.

1. 1CoImmune (United States) — Wikidatawikidata.org
2. 2CoImmune official websitecoimmune.com
3. 3CoImmune 任命两名董事加入董事会finanznachrichten.de